List view / Grid view
21 April 2016 | By Victoria White, Digital Content Producer
ARGX-115 targets the novel immuno-oncology target GARP, a protein believed to contribute to immunosuppressive effects of T-cells...
23 March 2016 | By Dr John Maher, Principal Investigator, National Institute for Health Research (NIHR) Biomedical Research Centre (BRC) at Guy’s and St Thomas’ and Kings College London
Here, Dr John Maher of the NIHR BRC at Guy's and St Thomas' and Kings College London discusses CAR T-cell therapy and the exciting frontier the technique has opened up in the battle against cancer...
22 March 2016 | By Victoria White
Celyad is teaming up with the Inserm Unit of Institut Curie in Paris, France, to further develop its NKR-T pipeline in cellular immunotherapies for cancer...
2 March 2016 | By Victoria White
The US Patent 9,273,283 is the second patent of Celyad allogeneic intellectual property portfolio that is awarded by the USPTO...
23 February 2016 | By Dr Frédéric Lehmann, VP Immuno-Oncology, Celyad
Natural killer receptor T-cells have the potential to become a real game changing treatment for patients with cancer. Here, Dr Frédéric Lehmann, VP Immuno-Oncology, Celyad, discusses this new cancer fighting technology...
18 February 2016 | By Victoria White
The results demonstrate that suppression of NR2F6 in T-cells results in increased expression of key immune stimulatory proteins IL-17 and IL-18...
16 February 2016 | By Victoria White
In one study, the engineered T-cells induced complete remission in 94% of patients with acute lymphoblastic leukaemia...
20 January 2016 | By Victoria White
Researchers have described a novel pathway called microptosis where the immune system's killer cells deliver a 3-phase knockout punch that kills intracellular parasites...
12 January 2016 | By Victoria White
A new study describes the design of a CAR architecture with an integrated switch-on system that permits control over CAR T-cell functions...
6 January 2016 | By Victoria White
The Cell Therapy Catapult, the University of Birmingham and Cancer Research Technology have launched the project to develop a new immuno-oncology cellular therapy based on gene modifying T-cells to target solid tumours...
5 January 2016 | By Victoria White
AIC649 is an inactivated parapoxvirus ovis particle preparation with distinct immunological activities including regulated cytokine release and activation of T-cell responses...
4 January 2016 | By Victoria White
UCART19 is a potential best-in-class allogeneic Talen gene edited T-cell product for treatment of CD19 expressing haematological malignancies...
8 December 2015 | By Victoria White
Doctors are harnessing patients’ own immune systems in a pioneering trial taking place in London in an effort to find a new effective treatment for resistant head and neck cancer...
1 December 2015 | By Victoria White
With Universal Cells’ proprietary gene editing technology, Adaptimmune intends to develop affinity enhanced donor T-cells...
26 October 2015 | By Victoria White
The US 9,181,527 Celyad Allogeneic Patent significantly strengthens Celyad’s patent portfolio in the CAR T-Cell field...
